deucravacitinib
bms
['ease,(-please),(-disease),(-incrrease),(-decrease)', 'deucra']
#acr22 plenary (1117) : phase 2 study of the tyk2 inhibitor deucravacitinib in patients with active #sle (mainly cutaneous/musculoskeletal).
=&gt; positive primary endpoint : increased sri-4 response at week32
=&gt; improvement of lldas, clasi50, bicla &amp; joint count. &gt;ms 
Annals of the Rheumatic Diseases (#1 research journal in Rheumatology) & RMD Open are the official @EULAR_ORG journals. High quality, peer reviewed research.